Skip to main content
SpringerLink
Log in
Book cover

Precision Medicine in Gynecology and Obstetrics pp 87–99Cite as

Prevention of Cervical Cancer: Era of HPV Testing and Vaccination

  • Chapter
  • First Online:

  • 831 Accesses

Part of the book series: Comprehensive Gynecology and Obstetrics ((CGO))

Abstract

The incidence and mortality of cervical cancer in young women of reproductive ages have recently increased, which is a serious issue worldwide. This chapter will focus on the prevention of cervical cancer with HPV testing and vaccination. It is recognized that strategies for preventing cervical cancer consist of two major steps: preventing infection of oncogenic human papillomavirus (HPV)-16 and HPV-18 by HPV vaccination and secondary prevention by screening using HPV testing and/or cytology. Current cervical cancer screening strategies using cytology combined with HPV testing have been successfully introduced, with shifting from cytology alone to cytology plus HPV cotesting and now to a new paradigm in which HPV testing alone may become a primary screening tool. HPV vaccination is a “primary prevention” tool, and both the bivalent and quadrivalent HPV vaccines have excellent safety and efficacy profiles. Recently, a 9-valent vaccine, targeted against HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58, has been developed, which may possibly protect against over 80% of invasive cervical cancers. Further evidence on the 9-valent HPV vaccine should be accumulated worldwide, and its application is expected as a new strategy. Finally, the WHO recognizes the prevention of cervical cancer and other HPV-related diseases as global public health problems and strongly recommends the HPV vaccination programs. Both HPV vaccination and cancer screening tests are indispensable for cervical cancer prevention. The complete eradication of this malignant disease in the world will be realized in the near future by the further development and widespread application of these two strategies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer, World Health Organization. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

  2. Motoki Y, Mizushima S, Taguri M, Takahashi K, Asano R, Kato H, Asai-Sato M, Katayama K, Okamoto N, Hirahara F, Miyagi E. Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: an analysis using the Kanagawa population-based Cancer Registry, 1975-2012. Cancer Epidemiol. 2015;39(5):700–6. doi:10.1016/j.canep.2015.08.001.

    Article  PubMed  Google Scholar 

  3. Yamagami W, Aoki D. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res. 2015;41:1861–9.

    Article  PubMed  Google Scholar 

  4. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465–91. http://www.who.int/wer

  5. Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, Hamada H, Yoshikawa H. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci. 2009;100(7):1312–6. doi:10.1111/j.1349-7006.2009.01161.x.

    Article  CAS  PubMed  Google Scholar 

  6. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810–9.

    Article  CAS  PubMed  Google Scholar 

  7. Spence AR, Coggin P, Franco EL. Process of care failures in invasive cervical cancer: a systematic review and meta-analysis. Prev Med. 2007;45:93–106. doi:10.1016/j.ypmed.2007.06.007.

    Article  PubMed  Google Scholar 

  8. Burd EM. Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev. 2016;29(2):291–319. doi:10.1128/CMR.00013-15.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cox JT, Castle PE, Behrens CM, Sharma A, Wright Jr TC, Cuzick J, Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184.e1–11. doi:10.1016/j.ajog.2012.11.020.

    Article  Google Scholar 

  10. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189–97. doi:10.1016/j.ygyno.2014.11.076.

    Article  PubMed  Google Scholar 

  11. Monsonego J, Cox JT, Behrens C, Sandri M, Franco EL, Yap PS, Huh W. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015;137(1):47–54. doi:10.1016/j.ygyno.2015.01.551.

    Article  PubMed  Google Scholar 

  12. Saslow D, Solomon D, Lawson HW, Killackey M, Kuasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs Jr LS, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiff-man M, Castle PE, Myers ER, ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72. doi:10.3322/caac.21139.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bailey HH, Chuang LT, duPont NC, Eng C, Foxhall LE, Merrill JK, Wollins DS, Blanke CD. American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention. J Clin Oncol. 2016;34(15):1803–12. doi:10.1200/JCO.2016.67.2014.

    Article  CAS  PubMed  Google Scholar 

  14. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.

    Article  Google Scholar 

  15. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet. 2009;374(9686):301–14. doi:10.1016/S0140-6736(09)61248-4.

    Article  CAS  PubMed  Google Scholar 

  16. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, Malloy M, Garland SM. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958–66. doi:10.1016/S1473-3099(14)70841-2.

    Article  PubMed  Google Scholar 

  17. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6(2):e009915. doi:10.1136/bmjopen-2015-009915.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458. doi:10.1136/bmj.g1458.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S, Donaghy M. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824–30. doi:10.1038/bjc.2014.479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Baldur-Felskov B, Munk C, Nielsen TS, Dehlendorff C, Kirschner B, Junge J, Kjaer SK. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control. 2015;26(8):1105–16. doi:10.1007/s10552-015-0603-7.

    Article  PubMed  Google Scholar 

  21. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906. doi:10.1136/bmj.f5906.

    Article  PubMed  PubMed Central  Google Scholar 

  22. European Medicine Agency (EMA). HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/11/news_detail_002436.jsp&mid=WC0b01ac058004d5c1

  23. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571. doi:10.1016/S0140-6736(15)61152-7.

    Article  PubMed  Google Scholar 

  24. Fujii T. Declaration to demand the resumption of recommendations for human papillomavirus (HPV) vaccination for cervical cancer prevention. J Obstet Gynaecol Res. 2015;41(12):1859–60.

    Article  PubMed  Google Scholar 

  25. The World Health Organization, Global Advisory Committee on Vaccine Safety. Statement on safety of HPV vaccines. 2015. http://www.who.int/vaccine_safety/committee/GACVS_HPV_statement_17Dec2015.pdf?ua=1

  26. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira Jr ED, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A, Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23. doi:10.1056/NEJMoa1405044.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-0012, Japan

    Kazuhiko Ino M.D., Ph.D.

Authors
  1. Kazuhiko Ino M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhiko Ino M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. National Kyoto Medical Center, Kyoto, Japan

    Ikuo Konishi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Ino, K. (2017). Prevention of Cervical Cancer: Era of HPV Testing and Vaccination. In: Konishi, I. (eds) Precision Medicine in Gynecology and Obstetrics. Comprehensive Gynecology and Obstetrics. Springer, Singapore. https://doi.org/10.1007/978-981-10-2489-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-2489-4_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-2488-7

  • Online ISBN: 978-981-10-2489-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation